PERSPECTA

News from every angle

Back to headlines

Jim Cramer Advises Caution on ImmunityBio

Jim Cramer recommended waiting for more clarity regarding ImmunityBio before investors consider a serious evaluation of the company's stock.

21 Apr, 17:19 — 21 Apr, 17:19
PostShare

Sources

Showing 1 of 1 sources